DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of ...

Explore DBV Technologies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DBVT. DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In ...

DBV Technologies stock opened at $4.19 on Thursday. The firm has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $3.83. The stock has a market capitalization of $86. ...

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.